ImmuCell Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ImmuCell.
Wichtige Informationen
n/a
Wachstumsrate der Gewinne
n/a
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 27.1% |
| Wachstumsrate der Einnahmen | n/a |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | None |
| Zuletzt aktualisiert | n/a |
Jüngste Aktualisierungen zum künftigen Wachstum
Keine Aktualisierungen
Recent updates
Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price
Aug 07
ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Aug 10Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price
May 27ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
Aug 11ImmuCell announces preliminary 2Q sales of $3.9M
Jul 07Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Sep 15Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation
Jun 10Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Mar 15Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?
Jan 22ImmuCell reports FY20 preliminary sales
Jan 07ImmuCell restructures its bank debt
Dec 15ImmuCell EPS beats by $0.04, beats on revenue
Nov 12In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da ImmuCell jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.
Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 6/30/2024 | 23 | -4 | -1 | 0 | N/A |
| 3/31/2024 | 21 | -4 | -3 | -1 | N/A |
| 12/31/2023 | 17 | -6 | -7 | -5 | N/A |
| 9/30/2023 | 16 | -6 | -9 | -5 | N/A |
| 6/30/2023 | 16 | -6 | -10 | -6 | N/A |
| 3/31/2023 | 16 | -5 | -9 | -5 | N/A |
| 12/31/2022 | 19 | -2 | -6 | -2 | N/A |
| 9/30/2022 | 20 | -1 | -3 | 0 | N/A |
| 6/30/2022 | 20 | 0 | -1 | 2 | N/A |
| 3/31/2022 | 21 | 1 | -1 | 2 | N/A |
| 12/31/2021 | 19 | 0 | -2 | 1 | N/A |
| 9/30/2021 | 18 | 0 | -2 | 1 | N/A |
| 6/30/2021 | 16 | 0 | -3 | 0 | N/A |
| 3/31/2021 | 15 | -1 | -3 | 0 | N/A |
| 12/31/2020 | 15 | -1 | -3 | 1 | N/A |
| 9/30/2020 | 15 | -2 | -3 | 1 | N/A |
| 6/30/2020 | 14 | -2 | -2 | 2 | N/A |
| 3/31/2020 | 14 | -2 | -2 | 0 | N/A |
| 12/31/2019 | 14 | -1 | -1 | 0 | N/A |
| 9/30/2019 | 13 | -2 | -1 | 0 | N/A |
| 6/30/2019 | 12 | -2 | -1 | 0 | N/A |
| 3/31/2019 | 13 | -2 | -1 | 0 | N/A |
| 12/31/2018 | 11 | -2 | -2 | 0 | N/A |
| 9/30/2018 | 11 | -1 | -7 | 0 | N/A |
| 6/30/2018 | 11 | -2 | -11 | 0 | N/A |
| 3/31/2018 | 10 | -1 | N/A | 0 | N/A |
| 12/31/2017 | 10 | 0 | N/A | 1 | N/A |
| 9/30/2017 | 10 | 0 | N/A | 0 | N/A |
| 6/30/2017 | 9 | 0 | N/A | 1 | N/A |
| 3/31/2017 | 10 | 1 | N/A | 1 | N/A |
| 12/31/2016 | 10 | 1 | N/A | 0 | N/A |
| 9/30/2016 | 10 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 11 | 1 | N/A | 2 | N/A |
| 3/31/2016 | 10 | 1 | N/A | 1 | N/A |
| 12/31/2015 | 10 | 1 | N/A | 3 | N/A |
| 9/30/2015 | 10 | 1 | N/A | 2 | N/A |
| 6/30/2015 | 9 | 1 | N/A | 1 | N/A |
| 3/31/2015 | 9 | 0 | N/A | 1 | N/A |
| 12/31/2014 | 8 | 0 | N/A | 0 | N/A |
| 9/30/2014 | 7 | 0 | N/A | 0 | N/A |
| 6/30/2014 | 6 | 0 | N/A | 0 | N/A |
| 3/31/2014 | 6 | 0 | N/A | 1 | N/A |
| 12/31/2013 | 6 | 0 | N/A | 1 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: Insufficient data to determine if ICCC's forecast earnings growth is above the savings rate (2.5%).
Ertrag vs. Markt: Insufficient data to determine if ICCC's earnings are forecast to grow faster than the US market
Hohe Wachstumserträge: Insufficient data to determine if ICCC's earnings are expected to grow significantly over the next 3 years.
Einnahmen vs. Markt: Insufficient data to determine if ICCC's revenue is forecast to grow faster than the US market.
Hohe Wachstumseinnahmen: Insufficient data to determine if ICCC's revenue is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if ICCC's Return on Equity is forecast to be high in 3 years time